#Anakinra for severe forms of #COVID-19: a cohort study

Coronaviruses can induce the production of interleukin (IL)-1Ξ², IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress … Continue reading #Anakinra for severe forms of #COVID-19: a cohort study